A Phase 2 interventional study of E7080 capsule in Thyroid Cancer, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-14.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2012, is one of 10 in phase 2, and was the 3rd registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Fudan University · Sites in China
Fujian Medical University · Sites in China
Ages 18–80
Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is close to the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 17 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
10 studies in Thyroid Neoplasms by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 10 studies in Thyroid Neoplasms by Eisai Co., Ltd., this one is the only one that started in 2012, is one of 4 in phase 2, and was the 4th registered.
Eisai Co., Ltd.’s Thyroid Neoplasms studies by the year they started, since 2005.
3 of the studies testing lenvatinib in Thyroid Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195228Fudan UniversityA Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | 2026-12-31 |
| NCT06848920Zhejiang UniversityStudy of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | 2027-06-30 |
| NCT04171622M.D. Anderson Cancer CenterLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 10 in Thyroid Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Participants with following complication or disease history
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: E7080 capsule
E7080 is administered as continuous once daily dosing in an uncontrolled manner
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Only TEAEs are included in the summary. For detailed list of adverse events (AEs), see the AE section. For each participant, only one TEAE in the same category was counted and for multiple TEAEs with different Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grades, only the event with the highest grade was reported. All AEs were graded using CTCAE v 4.0, except for alopecia and infertility.
Time frame: Screening visit to 30 days after the last dose of study drug, or assessed up to 3 years
Progression-free Survival (PFS)
PFS was defined as the time from (1) the date of randomization to the date of first documentation of disease progression based on Investigator and Independent Review Committee assessments according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), or (2) death, whichever came first. Disease progression for the MTC group was measured using computed tomography (CT) or magnetic resonance imaging (MRI) on targeted tumors. Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. Summarized by the Kaplan-Meier method using median time with 95% confidence interval (CI).
Time frame: From first date of study treatment until progression of disease or date of death from any cause, whichever comes first, assessed up to 34 months
Overall Survival (OS)
OS was defined as the time from the date of first dose of study treatment to the date of death from any cause. If death was not observed for a participant, the survival time was censored at the date the participant was last known alive or the data cutoff date (whichever occurred first). Summarized by the Kaplan-Meier method using median time with 95% CI.
Time frame: From study start until date of death from any cause, assessed up to 34 months
Best Overall Response (BOR)
BOR was defined as the best response observed between the time of first dose and the study completion, assessed by either of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). Tumor assessment was performed by the investigator using RECIST 1.1. The CR and PR were determined only when these responses met each criterion even after 28 days from the time observed. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as greater than or equal to 7 weeks for DTC and MTC, greater than or equal to 3 weeks for ATC.
Time frame: Date of first dose of study treatment to CR, PR, SD, PD, or NE, assessed up to 34 months
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had BOR of CR or PR. Tumor assessment was performed by the investigator using RECIST 1.1. ORR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.
Time frame: Date of CR or PR to date of PD or death (whichever was first), assessed up to 34 months
Disease Control Rate (DCR)
The DCR was defined as the percentage of participants who had BOR of CR, PR, or SD. Tumor assessment was performed by the investigator using RECIST 1.1. DCR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.
Time frame: Date of CR, PR, or SD to date of PD or death (whichever was first), assessed up to 34 months
Clinical Benefit Rate (CBR)
The CBR was defined as the percentage of participants who had BOR of CR, PR, or durable SD (dSD). Tumor assessment was performed by the investigator using RECIST 1.1. Durable stable disease was defined as SD lasting greater than or equal to 23 weeks for DTC and MTC, greater than or equal to 11 weeks for ATC. A 95% CI was calculated using exact method of binomial distribution.
Time frame: Date of CR, PR, or dSD to date of PD or death (whichever was first), assessed up to 34 months
| Milestone | Arm 4: Lenvatinib (MTC, DTC, ATC) |
|---|---|
| Started | 51 |
| Dtc | 25 |
| Mtc | 9 |
| Atc | 17 |
| Completed | 23 |
| Not completed | 28 |
| Withdrew: Disease progression | 26 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
Only TEAEs are included in the summary. For detailed list of adverse events (AEs), see the AE section. For each participant, only one TEAE in the same category was counted and for multiple TEAEs with different Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grades, only the event with the highest grade was reported. All AEs were graded using CTCAE v 4.0, except for alopecia and infertility.
| Percentage of participants | Arm 4: Lenvatinib (DTC, MTC, ATC) |
|---|---|
| TEAEs | 100.0 |
| CTCAE Grade 3 or 4 TEAEs | 82.4 |
| Serious TEAEs | 52.9 |
| TEAEs leading to study drug withdrawal | 2.0 |
| TEAEs leading to study drug reduction | 96.1 |
| TEAEs leading to study drug interruption | 66.7 |
PFS was defined as the time from (1) the date of randomization to the date of first documentation of disease progression based on Investigator and Independent Review Committee assessments according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), or (2) death, whichever came first. Disease progression for the MTC group was measured using computed tomography (CT) or magnetic resonance imaging (MRI) on targeted tumors. Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. Summarized by the Kaplan-Meier method using median time with 95% confidence interval (CI).
| Months | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| Progression-free Survival (PFS) | 25.8 (18.4 to NA) | 9.2 (1.8 to NA) | 7.4 (1.7 to 12.9) |
OS was defined as the time from the date of first dose of study treatment to the date of death from any cause. If death was not observed for a participant, the survival time was censored at the date the participant was last known alive or the data cutoff date (whichever occurred first). Summarized by the Kaplan-Meier method using median time with 95% CI.
| Months | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| Overall Survival (OS) | 31.8 (31.8 to NA) | 12.1 (3.8 to NA) | 10.6 (3.8 to 19.8) |
BOR was defined as the best response observed between the time of first dose and the study completion, assessed by either of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). Tumor assessment was performed by the investigator using RECIST 1.1. The CR and PR were determined only when these responses met each criterion even after 28 days from the time observed. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as greater than or equal to 7 weeks for DTC and MTC, greater than or equal to 3 weeks for ATC.
| Percentage of participants | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 68.0 | 22.2 | 23.5 |
| SD | 32.0 | 77.8 | 70.6 |
| PD | 0 | 0 | 5.9 |
| NE | 0 | 0 | 0 |
ORR was defined as the percentage of participants who had BOR of CR or PR. Tumor assessment was performed by the investigator using RECIST 1.1. ORR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.
| Percentage of participants | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| Objective Response Rate (ORR) | 68.0 (46.5 to 85.1) | 22.2 (2.8 to 60.0) | 23.5 (6.8 to 49.9) |
The DCR was defined as the percentage of participants who had BOR of CR, PR, or SD. Tumor assessment was performed by the investigator using RECIST 1.1. DCR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.
| Percentage of participants | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| Disease Control Rate (DCR) | 100.0 (86.3 to 100.0) | 100.0 (66.4 to 100.0) | 94.1 (71.3 to 99.9) |
The CBR was defined as the percentage of participants who had BOR of CR, PR, or durable SD (dSD). Tumor assessment was performed by the investigator using RECIST 1.1. Durable stable disease was defined as SD lasting greater than or equal to 23 weeks for DTC and MTC, greater than or equal to 11 weeks for ATC. A 95% CI was calculated using exact method of binomial distribution.
| Percentage of participants | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 84.0 (63.9 to 95.5) | 77.8 (40.0 to 97.2) | 70.6 (44.0 to 89.7) |
Collected over AEs were collected for up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 4: Lenvatinib (DTC, MTC, ATC) | 4/51 (7.8%) | 27/51 (52.9%) | 51/51 (100%) |
| Event | Arm 4: Lenvatinib (DTC, MTC, ATC) |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 7/51 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/51 |
| PneumoniaInfections and infestations | 3/51 |
| NauseaGastrointestinal disorders | 2/51 |
| Laryngeal stenosisRespiratory, thoracic and mediastinal disorders | 2/51 |
| DiarrhoeaGastrointestinal disorders | 1/51 |
| DysphagiaGastrointestinal disorders | 1/51 |
| Gastric ulcerGastrointestinal disorders | 1/51 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/51 |
| FatigueGeneral disorders | 1/51 |
| Event | Arm 4: Lenvatinib (DTC, MTC, ATC) |
|---|---|
| HypertensionVascular disorders | 46/51 |
| Decreased appetiteMetabolism and nutrition disorders | 39/51 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 39/51 |
| FatigueGeneral disorders | 37/51 |
| ProteinuriaRenal and urinary disorders | 31/51 |
| StomatitisGastrointestinal disorders | 29/51 |
| DiarrhoeaGastrointestinal disorders | 27/51 |
| NauseaGastrointestinal disorders | 21/51 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 21/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/51 |
Safety analysis set included all participants who received at least one dose of study drug and had at least one postbaseline safety evaluation.
| Age, Continuous(years) | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) | Total |
|---|---|---|---|---|
| Mean | 57.1 ± 12.34 | 60.6 ± 13.70 | 63.4 ± 11.40 | 59.8 ± 12.36 |
| Sex: Female, Male(Participants) | Lenvatinib (Arm 1) | Lenvatinib (Arm 2) | Lenvatinib (Arm 3) | Total |
|---|---|---|---|---|
| Female | 16 | 3 | 11 | 30 |
| Male | 9 | 6 | 6 | 21 |
Ran from Sep 2012 to primary completion in Jul 2015, 34 months.
Results were first posted in Aug 2020, 5 years 1 month after primary completion.
Of 92 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib